Preview

Современная ревматология

Расширенный поиск

Возможности применения лефлуномидапри ревматических заболеваниях

https://doi.org/10.14412/1996-7012-2011-652

Полный текст:

Аннотация

Представленные данные литературы открывают новые возможности применения лефлуномида в ревматологии. Проведенные испытания позволяют рассматривать лефлуномид как перспективный препарат при воспалительных заболеваниях суставов и позвоночника. Обнадеживающие результаты предварительных исследований эффективности лефлуномида при болезни Крона, гранулематозе Вегенера и системной красной волчанке требуют подтверждения в масштабных рандомизированных контролируемых исследованиях.

Литература

1. <div><p>Насонов Е.Л. Перспективы комбинированной терапии ревматоидного артрита - лефлуномид и инфликсимаб. РМЖ 2008;16(10):633-7.</p><p>Чичасова Н.В., Чижова К.А., Иголкина Е.В. и др. Новый базисный препарат для лечения ревматоидного артрита - Арава: подавление активности и прогрессирования болезни. Врач 2004;4:43-6.</p><p>Балабанова Р.М., Каратеев Д.Е., Кашеваров Р.Ю. и др. Лефлуномид (Арава) при раннем ревматоидном артрите. Науч-практич ревматол 2005;5:31-4.</p><p>Finckh A., Dechler S., Gabay C. Effectiveness of leflunomide as co-therapy of TNF inhibitors in rheumatoid arthritis. A population based study. Ann Rheum Dis 2008;69:136-41.</p><p>Kalden J.R., Antoni C., Alvaro-Gracia J.M. et al. Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. J Rheum 2005;32:1620-31.</p><p>Weinblatt M., Kremer J.M., Colin J.S. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthr Rheum 1999;42:1322.</p><p>Bingham S.J., Buch M.H., Kerr M.A. et al. Induction of antinuclear antibodes in patients with rheumatoid arthritis treated with infliximab and leflunomide. Arthr Rheum 2004;50:4072-3.</p><p>Kremer J.M. Methotrexate and leflunomide: biochemical basis for combination therapy in treatment of rheumatoid arthritis. Arthr Rheum 1999;29:14-26.</p><p>Black R.L., O'Brien W.M., van Scott E.J. et al. Methotrexate therapy in psoriatic arthritis. JAMA 1964;189:743-7.</p><p>Clegg D.O., Reda D.J., Mejias E. et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthr Rheum 1996;39:2013-20.</p><p>Jones G., Crotty M., Brooks P. Intervention for psoriatic arthritis (Cohrane review). In: The Cohrane Library, Issue 1. Oxford: Update Software, 2001.</p><p>Tassiulas I., Duncan S.R., Theofilopoulos A.N. et al. Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immun 1999;60:479-91.</p><p>Liang G.C., Barr W.G. Leflunomide for refractory psoriasis and psoriatic arthritis. J Clin Rheum 2001;7:366-70.</p><p>Reich K., Hummel K.M., Beckmann I. et al. Treatment of severe psoriasis and psoriatic arthritis with leflunomide. Br J Dermat 2002;146:335-6.</p><p>Tlacuilo-Parra J.A., Guevara-Gutierrez E., Rodriguez-Castellanos M.A. et al. Leflunomide in the treatment of psoriasis: results of a Phase II open trial. Br J Dermat 2004;150:970-6.</p><p>Cuchacovich M., Soto L. Leflunomide decreases joint erosions and induces reparative changes in a patient with psoriatic arthritis. Ann Rheum Dis 2002;61:942-3.</p><p>Kaltwasser J.P., Nash P., Gladman D. et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. A multinational, double-blind, randomized, placebo-controlled clinical trial. Arhtr Rheum 2004;50:1939-50.</p><p>Bollow M., Fischer T., Reisshauer H. et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis - cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000;59:135-40.</p><p>Haibel H., Rudwaleit M., Braun J. et al. Six months open label trial of leflunomide in active ankylosing spondylitis Ann Rheum Dis 2005;64:124-6. DOI:10.1136/ard.2003.019174.</p><p>Van Denderen J.C., van der Paardt M., Nurmohamed M.T. et al. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis 2005;64:1761-4. DOI: 10.1136/ard.2005.036491.</p><p>Vandooren B., Kruithof E., Yu D.T. et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor α blockade in spondylarthropathy. Arthr Rheum 2004;50:2942-53.</p><p>Prajapati D.N., Knox J.F., Emmons J. et al. Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy. J Clin Gastroent 2003;37:125-8.</p><p>Holtmann M.H., Gerts A.L., Weinman A. et al. Treatment of Crohn's disease with leflunomide as second-line immunosuppression: a phase 1 open-label trial on efficacy, tolerability and safety. Dig Dis Sci 2008;53(4):1025-32. Epub 2007 Oct 13.</p><p>Silverman E., Mouy R., Spiegel L. et al. Durability of efficacy, safety, and tolerability of leflunomide (LEF) versus methotrexate (MTX) in the treatment of pediatric patients with juvenile rheumatoid arthritis (JRA). The 68th Annual Meeting of the American College of Rheumatology, 2004, Post. 72.</p><p>Metzler C., Fink C., Lampracht P. et al. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology 2004;43:315-20.</p><p>Metzler C., Miehle N., Manger K. et al. Reinhold-Keller for the German Network of Rheumatic Diseases Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology 2007;46;1087-91.</p><p>Verstappen J., van Roon A.G., Bijlsma W.J. et al. Safety and efficacy of Leflunomide in primary Sjo gren's syndrome - A phase II pilot study. Ann Rheum Dis published online 2007, 12 Jan.</p><p>Vitali C., Bombardieri S., Jonsson R. et al. Classification criteria for Sjo gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.</p><p>Remer C.F., Weisman M.H., Wallace D.J. Benefits of leflunomide in systemic lupus erythematosus: a pilot observation study. Lupus 2001;10:480-3.</p><p>Tam L.-S., Li E.K., Wong C.-K. et al. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 2004;13:601-4.</p></div><br />


Для цитирования:


Иголкина Е.В., Чичасова Н.В., Имаметдинова Г.Р., Насонов Е.Л., Иголкина Е.В., Чичасова Н.В., Имаметдинова Г.Р., Насонов Е.Л. Возможности применения лефлуномидапри ревматических заболеваниях. Современная ревматология. 2011;5(1):54-57. https://doi.org/10.14412/1996-7012-2011-652

For citation:


Igolkina E.V., Chichasova N.V., Imametdinova G.R., Nasonov E.L., Igolkina E.V., Chichasova N.V., Imametdinova G.R., Nasonov E.L. POSSIBILITIES OF USING LEFLUNOMIDE IN RHEUMATIC DISEASES. Modern Rheumatology Journal. 2011;5(1):54-57. (In Russ.) https://doi.org/10.14412/1996-7012-2011-652

Просмотров: 908


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)